Ustekinumab beats placebo for ulcerative colitis

International trial showed subcutaneous maintenance therapy to be effective

Patients with moderate to severe ulcerative colitis are more likely to achieve clinical remission and a range of other outcomes on ustekinumab than placebo, according to the results of a phase 3 trial.